CSPC Pharmaceutical Group (HKG:1093) said China's National Medical Products Administration (NMPA) granted new drug registration approval to Aprepitant Injection, according to a Monday filing with the Hong Kong bourse.
Aprepitant Injection is a submicron emulsion injection of a neurokinin-1 (NK1) receptor antagonist. It is aimed at preventing nausea and vomiting with highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC) in adult patients.
The company's stocks were down by 2% in recent trading.
Price (HKD): $4.57, Change: $-0.090, Percent Change: -1.93%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.